Publication: Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
Issued Date
2010-08
Resource Type
Language
eng
File Type
application/pdf
No. of Pages/File Size
129130 bytes
ISSN
1947-2714 (electronic)
2250-1541 (printed)
2250-1541 (printed)
Rights
Mahidol University
Rights Holder(s)
American journal of the medical sciences
Bibliographic Citation
Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. N Am J Med Sci. 2010 Aug;2(8):365-70.
Suggested Citation
Aung, Myo Nyein, Wattana Leowattana, วัฒนา เลี้ยววัฒนา, Noppadon Tangpukdee, Chatporn Kittitrakul Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. N Am J Med Sci. 2010 Aug;2(8):365-70.. doi:10.4297/najms.2010.2365 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/776
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
Corresponding Author(s)
Abstract
Background: Hepatitis B genotypes influence the course and severity of the disease. Aim: To compare the treatment outcome of chronic hepatitis B genotype B and C patients after treating with nucleos(t)ide analogues for six months. Patients and Methods: Forty chronic hepatitis B patients attending the liver clinic of Hospital for Tropical diseases, Bangkok, were studied in retrospective cohort design. Six genotype B patients (15%) and thirty-four genotype C patients (85%) were treated. Serum hepatitis B viral load , serum alanine amino transferase level, HBeAg status and alpha-feto protein level were measured at the time of starting nucleos(t) analogues therapy, and six months later. Besides, achievement of undetectable viral load was assessed in patients with normal serum alanine amino transferase compared to patients with high serum alanine amino transferase level. Results: After six months of nucleos (t) analogues treatment, achievement of undetectable hepatitis B viral load was higher in genotype B patients (66.7%) than in genotype C patients (42.4%) (Relative Risk=1.57, 0.79-3.14). Biochemical remission, HBeAg seroconversion and tumor marker levels between the two groups were not significantly different. Moreover, achievement of undetectable hepatitis B viral load was significantly higher in normal alanine amino transferase level (75%) than in patients with high serum alanine amino transferase level (33.3%) on nucleos(t)ide analogue treatment (Relative Risk=2.25, 1.20- 4.20). Conclusion: Chronic hepatitis B treatment outcome between genotype B and C were not significantly different. Patients with normalized serum alanine amino transferase level tend to achieve undetectable viral load after nucleoside analogues treatment.